TITLE

Single-Center Experience With Cyclosporine for Treatment of Idiopathic Minimal Change Nephrotic Syndrome in Children

AUTHOR(S)
Sabry, Alaa; El-Husseini, Amr; El-Dahshan, Khaled; Sobh, Mohamed
PUB. DATE
July 2009
SOURCE
Iranian Journal of Kidney Diseases;Jul2009, Vol. 3 Issue 3, p127
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction. Cyclosporine A is used in the treatment of idiopathic nephrotic syndrome. We conducted this study to evaluate the effect of cyclosporine and its combination with ketoconazole in Egyptian nephrotic children with steroid-resistant and steroid-dependant minimal change. Materials and Methods. Forty-eight children with minimal change lesions who received cyclosporine with or without ketoconazole were studied. Their mean age was 5.17 ± 1.59 years, and they were 31 boys and 17 girls. The mean duration of the disease was 6.22 ± 3.16 years. Thirty-one of the children were steroid dependent and 17 were steroid resistant. Cyclosporine treatment was commenced after remission was attained and adjusted to a target trough level of 100 ng/mL. The mean cyclosporine therapy at a dose of 2.07 ± 0.91 mg/kg was administered for a mean of 25.75 ± 1.95 months. Thirty-three patients received adjunctive ketoconazole therapy. Results. Thirty-eight patients (79.2%) responded well to cyclosporine. Steroid therapy could be discontinued in 43 patients (89.6%), but 9 experienced relapse. Ten patients (20.8%) were resistant to cyclosporine therapy. Fifteen patients received cyclosporine alone, while 33 received concomitant cyclosporine and ketoconazole. The response to cyclosporine was significantly better in those on ketoconazole. The economic effect of ketoconazole therapy was a reduction in the costs of cyclosporine treatment by 47.4% at 1 year of treatment. Conclusions. Cyclosporine treatment in children with minimal change nephrotic syndrome is effective in preventing relapse and decreasing steroid toxicity. Its combination with low-dose ketoconazole is safe, reduces treatment costs, and improves the response to cyclosporine.
ACCESSION #
48665683

 

Related Articles

  • Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Tejani, Amir; Butt, Khalid; Trachtman, Howard; Suthanthiran, Manikkam; Rosenthal, Constantine J.; Khawar, Mohamed R. // Kidney International;Mar1988, Vol. 33 Issue 3, p729 

    We treated 20, steroid resistant or steroid dependent and cyclophosphamide or chlorambucil treated, relapsing nephrotic patients with oral cyclosporine A for eight weeks. Cyclosporine A was started at 7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of 20 patients, 14 had a...

  • Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Dorresteijn, Eiske M.; Kist-van Holthe, Joana E.; Levtchenko, Elena N.; Nauta, Jeroen; Hop, Wim C. J.; van der Heijden, Albert J. // Pediatric Nephrology;Nov2008, Vol. 23 Issue 11, p2013 

    We performed a multi-centre randomized controlled trial to compare the efficacy of mycophenolate mofetil (MMF) to that of cyclosporine A (CsA) in treating children with frequently relapsing nephrotic syndrome and biopsy-proven minimal change disease. Of the 31 randomized initially selected...

  • Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. El-Husseini, Amr; El-Basuony, Fathy; Mahmoud, Ihab; Donia, Ahmed; Sheashaa, Hussein; Sabry, Alaa; Hassan, Nabil; Sayed-Ahmad, Nagy; Sobh, Mohamed // European Journal of Clinical Pharmacology;Jan2006, Vol. 62 Issue 1, p3 

    Background: Children with steroid-dependent nephrotic syndrome experience serious side effects from steroid therapy. Cyclosporine A (CsA), which is an effective agent in the treatment of steroid-dependent nephrotic syndrome, is expensive and, consequently, often unaffordable in developing...

  • A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Fujinaga, Shuichiro; Ohtomo, Yoshiyuki; Umino, Daisuke; Takemoto, Mayako; Shimizu, Toshiaki; Yamashiro, Yuichiro; Kaneko, Kazunari // Pediatric Nephrology;Jan2007, Vol. 22 Issue 1, p71 

    Cyclosporine A (CsA) has relieved children with steroid-dependent nephrotic syndrome (NS) from steroid toxicity. However, most patients frequently relapse again when CsA is withdrawn, resulting in the development of CsA nephropathy for its long-term use. In order to assess the efficacy of...

  • Decreased cyclosporine exposure during the remission of nephrotic syndrome. Medeiros, Mara; P�rez-Urizar, Jos�; Mej�a-Gaviria, Natalia; Ram�rez-L�pez, Eduardo; Casta�eda-Hern�ndez, Gilberto; Mu�oz, Ricardo // Pediatric Nephrology;Jan2007, Vol. 22 Issue 1, p84 

    In this paper, we report the pharmacokinetics changes observed in seven children with steroid-resistant nephrotic syndrome (SRNS). They received cyclosporine A (CsA) microemulsion 6 mg/kg/day and, one week later, they were admitted to perform a 12-h pharmacokinetic profile with eight time sample...

  • Treating Pediatric Nephrotic Syndrome: A Clinical Challenge. Broome, Laura F.; Szromba, Charlotte // Nephrology Nursing Journal;Dec2003, Vol. 30 Issue 6, p662 

    Provides information on several treatment options for pediatric patients with nephrotic syndrome. Symptoms exhibited by patients with nephrotic syndrome; Effectiveness of a macrolide immunosuppressant drug in treating steroid resistant and steroid-dependent nephrotic syndrome patients; Sytems...

  • Interventions for steroid-resistant nephrotic syndrome: a systematic review. Habashy, Doaa.; Hodson, Elisabeth M.; Craig, Jonathan C. // Pediatric Nephrology;Sep2003, Vol. 18 Issue 9, p906 

    In a systematic review and meta-analysis of randomized controlled trials (RCT), we aimed to evaluate the benefits and harms of all interventions for children with steroid-resistant nephrotic syndrome (SRNS). Nine RCTs involving 225 children were included. Cyclosporin when compared with placebo...

  • 39th and 40th Annual Meeting of the Japanese Society for Pediatric Nephrology, 2004 and 2005.  // Pediatric Nephrology;Sep2006, Vol. 21 Issue 9, p1335 

    The article presents abstracts of medical research presented at the 39th and 40th Annual Meetings of the Japanese Society for Pediatric Nephrology in 2004 and 2005. They include: "Therapeutic effects of mycophenolate mofetil (MMF) on multidrug-resistant, intractable nephrotic syndrome," "Segment...

  • Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Wasilewska, Anna; Zoch-Zwierz, Walentyna; Taranta-Janusz, Katarzyna; Michaluk-Skutnik, Joanna // Pediatric Nephrology;May2010, Vol. 25 Issue 5, p889 

    The aim of work was to investigate whether serum and urinary neutrophil gelatinase-associated lipocalin (sNGAL and uNGAL, respectively) are potential biomarkers of early cyclosporine A (CsA) nephrotoxicity in steroid-dependent nephrotic children (SDNS). The study group (I) consisted of 19...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics